174 related articles for article (PubMed ID: 35635854)
1. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.
Wang N; Shi D; Li N; Qi H
Ann Med; 2021 Dec; 53(1):2041-2049. PubMed ID: 34927512
[TBL] [Abstract][Full Text] [Related]
4. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders.
Alessandrini L; Aryananda R; Ariani G; Agustina B; Akbar MIA; Dachlan EG; Dekker G; Ernawati E
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183744. PubMed ID: 36859823
[TBL] [Abstract][Full Text] [Related]
5. Comparison of circulating total sFLT-1 to placental-specific sFLT-1 e15a in women with suspected preeclampsia.
Rowson S; Reddy M; De Guingand DL; Langston-Cox A; Marshall SA; da Silva Costa F; Palmer KR
Placenta; 2022 Mar; 120():73-78. PubMed ID: 35227983
[TBL] [Abstract][Full Text] [Related]
6. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
7. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
[TBL] [Abstract][Full Text] [Related]
8. Serum angiogenic profile in abnormal placentation.
Biberoglu E; Kirbas A; Daglar K; Biberoglu K; Timur H; Demirtas C; Karabulut E; Danisman N
J Matern Fetal Neonatal Med; 2016 Oct; 29(19):3193-7. PubMed ID: 26863111
[TBL] [Abstract][Full Text] [Related]
9. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
[TBL] [Abstract][Full Text] [Related]
10. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
[TBL] [Abstract][Full Text] [Related]
11. Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders.
Arakaza A; Liu X; Zhu J; Zou L
J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2305264. PubMed ID: 38247274
[TBL] [Abstract][Full Text] [Related]
12. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
13. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
14. Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia.
Lecarpentier E; Zsengellér ZK; Salahuddin S; Covarrubias AE; Lo A; Haddad B; Thadhani RI; Karumanchi SA
Hypertension; 2020 Sep; 76(3):875-883. PubMed ID: 32654553
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
[TBL] [Abstract][Full Text] [Related]
16. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?
Stepan H; Hund M; Dilba P; Sillman J; Schlembach D
Clin Chem Lab Med; 2019 Aug; 57(9):1339-1348. PubMed ID: 31323000
[TBL] [Abstract][Full Text] [Related]
17. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
[TBL] [Abstract][Full Text] [Related]
18. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
[TBL] [Abstract][Full Text] [Related]
19. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
[TBL] [Abstract][Full Text] [Related]
20. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
Wehrum MJ; Buhimschi IA; Salafia C; Thung S; Bahtiyar MO; Werner EF; Campbell KH; Laky C; Sfakianaki AK; Zhao G; Funai EF; Buhimschi CS
Am J Obstet Gynecol; 2011 May; 204(5):411.e1-411.e11. PubMed ID: 21316642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
